References
Talbot JN, Montravers F, Kerrou K, Nataf V, Chevalme Y. FDOPA PET has clinical utility in brain tumour imaging: a proposal for a revision of the recent EANM guidelines. Eur J Nucl Med Mol Imaging 2007; in press. DOI 10.1007/s00259-007-0400-y.
Vander Borght T, Asenbaum S, Bartenstein P, Halldin C, Kapucu O, Van Laere K, et al. EANM procedure guidelines for brain tumour imaging using labelled amino acid analogues. Eur J Nucl Med Mol Imaging 2006;33:1374–80.
Chen W, Delaloye S, Czernin J, Silverman DH, Pope W, Satyamurthy N, et al. Predicting response of malignant brain tumors to bevacizumab and irinotecan therapy with FLT and FDOPA PET. SNM annual meeting 2006, N° 221.
Chen W, Delaloye S, Cloughesy T, Mischel P, Bergsneider M, Satyamurthy N, et al. FDOPA uptake kinetics in human gliomas and the relationship to histopathologic tumor cell proliferation index Ki-67. SNM annual meeting 2006, N° 222.
Heiss WD, Wienhard K, Wagner R, Lanfermann H, Thiel A, Herholz K, et al. F-dopa as an amino acid tracer to detect brain tumors. J Nucl Med 1996;37:1180–2.
Becherer A, Karanikas G, Szabo M, Zettinig G, Asenbaum S, Marosi C, et al. Brain tumour imaging with PET: a comparison between [18F]fluorodopa and [11C]methionine. Eur J Nucl Med Mol Imaging 2003;30:1561–7.
Chen W, Silverman DH, Delaloye S, Czernin J, Kamdar N, Pope W, et al. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med 2006;47:904–11.
Author information
Authors and Affiliations
Corresponding author
Additional information
This reply refers to the letter to the editor at doi:10.1007/s00259-007-0400-y.
Rights and permissions
About this article
Cite this article
Vander Borght, T., Asenbaum, S., Bartenstein, P. et al. Reply. Eur J Nucl Med Mol Imaging 34, 1133–1134 (2007). https://doi.org/10.1007/s00259-007-0408-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00259-007-0408-3